Generalized Anxiety Disorder

Categories: Genetic diseases, Mental diseases

Aliases & Classifications for Generalized Anxiety Disorder

MalaCards integrated aliases for Generalized Anxiety Disorder:

Name: Generalized Anxiety Disorder 12 74 36 54 15 62 17 71 32
Anxiety Generalized 54


External Ids:

Disease Ontology 12 DOID:14320
KEGG 36 H01662
ICD9CM 34 300.02
NCIt 49 C92622
SNOMED-CT 67 21897009
ICD10 32 F41.1
UMLS 71 C0270549

Summaries for Generalized Anxiety Disorder

PubMed Health : 62 About generalized anxiety disorder: Everyone feels frightened or very scared every once in a while. In dangerous situations, for instance on the highway, fear can help to protect you. It puts the body in a state of readiness so that it can react to threats quickly. Worries and anxiety about the future, your job or family might also help to guard against danger. For example, by keeping you from making rash decisions that could lead to difficult situations. But if these sorts of fears become overwhelming, they can be very distressing. Some people end up constantly worrying about practically everything. If fears and anxiety overshadow everything else and don’t go away, the person may have developed generalized anxiety disorder (GAD). People with generalized anxiety disorder usually realize that their fears are exaggerated, but they aren’t able to control them. Although it’s difficult to get out of this state, there are treatments that can help.

MalaCards based summary : Generalized Anxiety Disorder, also known as anxiety generalized, is related to neurotic disorder and depression. An important gene associated with Generalized Anxiety Disorder is HTR1A (5-Hydroxytryptamine Receptor 1A), and among its related pathways/superpathways are cAMP signaling pathway and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Eszopiclone and Norepinephrine have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An anxiety disorder that is characterized by long-lasting anxiety that is not focused on any one object or situation.

KEGG : 36 Generalized anxiety disorder is a persistent and common mental disorder. This disorder is twice as common in women than it is in men. The symptoms include generalised and persistent excessive anxiety and a combination of various psychological and somatic complaints, such as threat, restlessness, irritability, sleep disturbance, tension, palpitations, dry mouth, and sweating. The symptoms overlap greatly with those of other mental disorders and we could regard the disorder as part of a spectrum of mood and related disorders rather than an independent disorder. Generalized anxiety disorder has a relapsing course, and intervention rarely results in complete resolution of symptoms. But in the short term and medium term, effective treatments include psychological therapies, such as cognitive behavioural therapy, and pharmacological treatments, mainly selective serotonin reuptake inhibitors (SSRIs).

Wikipedia : 74 Generalized anxiety disorder (GAD) is an anxiety disorder characterized by excessive, uncontrollable and... more...

Related Diseases for Generalized Anxiety Disorder

Diseases related to Generalized Anxiety Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 252)
# Related Disease Score Top Affiliating Genes
1 neurotic disorder 32.6 SLC6A4 MAOA HTR2A HTR1A BDNF
2 depression 32.5 TPH1 SLC6A4 MAOA HTR2A HTR1A CRHR1
3 dysthymic disorder 31.1 SLC6A4 MAOA HTR2A HTR1A BDNF
4 avoidant personality disorder 31.1 TPH1 SLC6A4 SLC6A3 MAOA
5 social phobia 31.1 SLC6A4 MAOA HTR3A HTR1A DRD2 COMT
6 somatization disorder 31.0 SLC6A4 HTR2A
7 agoraphobia 30.8 SLC6A4 SLC6A2 RGS2 MAOA HTR2A HTR1A
8 acute stress disorder 30.8 SLC6A4 NR3C1 CRP CRHR1 BDNF
9 phobia, specific 30.8 SLC6A4 MAOA HTR1A COMT
10 withdrawal disorder 30.8 TSPO HTR1A DRD2 CRHR1
11 sexual disorder 30.7 SLC6A4 HTR3A HTR2A HTR1A DRD2 CYP2D6
12 obsessive-compulsive personality disorder 30.7 SLC6A4 HTR2A COMT
13 hypochondriasis 30.6 SLC6A4 HTR3A HTR2A HTR1A BDNF
14 alexithymia 30.5 SLC6A4 HTR1A DRD2 CRP COMT
15 postpartum depression 30.4 SLC6A4 NR3C1 MAOA HTR1A COMT BDNF
16 anxiety 30.3 TSPO TPH1 SLC6A4 SLC6A3 SLC6A2 RGS2
17 conversion disorder 30.3 HTR2A COMT
18 antisocial personality disorder 30.3 SLC6A4 SLC6A3 MAOA HTR2A DRD2 COMT
19 adjustment disorder 30.3 TSPO SLC6A4 NPY HTR2A HTR1A BDNF
20 alcohol use disorder 30.3 SLC6A4 SLC6A3 HTR3A HTR2A HTR1A DRD2
21 eating disorder 30.3 SLC6A4 SLC6A3 NPY HTR2A DRD2 COMT
22 bruxism 30.2 SLC6A4 HTR2A HTR1A DRD2
23 bipolar i disorder 30.2 SLC6A4 HTR2A HTR1A DRD2 COMT BDNF
24 phobic disorder 30.2 SLC6A4 MAOA HTR2A HTR1A DRD2 CRHR1
25 movement disease 30.1 SLC6A3 DRD2 CYP2D6
26 obsessive-compulsive disorder 30.1 TPH1 SLC6A4 SLC6A3 NPY MAOA HTR3A
27 irritable bowel syndrome 30.1 TPH1 SLC6A4 HTR3A HTR2A HTR1A CRP
28 tic disorder 30.0 SLC6A4 SLC6A3 MAOA HTR2A HTR1A DRD2
29 neuroleptic malignant syndrome 30.0 HTR3A HTR2A HTR1A DRD2 CYP2D6
30 panic disorder 30.0 TSPO TPH1 SLC6A4 SLC6A3 SLC6A2 RGS2
31 oppositional defiant disorder 29.9 SLC6A4 SLC6A3 SLC6A2 MAOA DRD2 COMT
32 melancholia 29.9 SLC6A4 MAOA HTR2A HTR1A CRP BDNF
33 serotonin syndrome 29.9 SLC6A4 MAOA HTR3A HTR2A HTR1A CYP2D6
34 mental depression 29.9 TPH1 SLC6A4 SLC6A3 SLC6A2 NR3C1 MAOA
35 personality disorder 29.9 TPH1 SLC6A4 SLC6A3 NR3C1 MAOA HTR3A
36 constipation 29.8 TPH1 SLC6A4 SLC6A2 NPY HTR3A HTR2A
37 substance abuse 29.8 SLC6A4 SLC6A3 NPY MAOA HTR2A HTR1A
38 substance dependence 29.7 TPH1 SLC6A4 SLC6A3 MAOA DRD2 CYP2D6
39 sleep disorder 29.7 SLC6A4 SLC6A3 HTR2A HTR1A DRD2 CRP
40 post-traumatic stress disorder 29.7 SLC6A4 NR3C1 NPY MAOA HTR2A HTR1A
41 fibromyalgia 29.7 TSPO SLC6A4 NPY HTR3A HTR2A HTR1A
42 anorexia nervosa 29.7 TPH1 SLC6A4 SLC6A2 NPY MAOA HTR2A
43 mood disorder 29.6 TPH1 SLC6A4 SLC6A3 SLC6A2 NR3C1 NPY
44 bulimia nervosa 29.5 SLC6A4 NPY MAOA HTR3A HTR2A DRD2
45 chronic fatigue syndrome 29.5 SLC6A4 NR3C1 NPY MAOA HTR3A HTR2A
46 myocardial infarction 29.5 SLC6A4 NPY HTR3A HTR2A CRP COMT
47 dementia 29.5 TSPO SLC6A3 HTR2A HTR1A DRD2 CYP2D6
48 tobacco addiction 29.5 TPH1 SLC6A4 SLC6A3 MAOA HTR2A DRD2
49 psychotic disorder 29.5 TPH1 SLC6A4 SLC6A3 MAOA HTR3A HTR2A
50 major depressive disorder 29.3 TPH1 SLC6A4 SLC6A3 SLC6A2 NR3C1 NPY

Comorbidity relations with Generalized Anxiety Disorder via Phenotypic Disease Network (PDN): (show all 18)

Acute Cystitis Anxiety
Bronchitis Dependent Personality Disorder
Dysthymic Disorder Esophagitis
Histrionic Personality Disorder Hypertension, Essential
Hypochondriasis Hypothyroidism
Irritable Bowel Syndrome Major Depressive Disorder
Obsessive-Compulsive Disorder Obsessive-Compulsive Personality Disorder
Osteoporosis Personality Disorder
Schizophreniform Disorder Somatization Disorder

Graphical network of the top 20 diseases related to Generalized Anxiety Disorder:

Diseases related to Generalized Anxiety Disorder

Symptoms & Phenotypes for Generalized Anxiety Disorder

GenomeRNAi Phenotypes related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 9.85 MAOA NR3C1
2 Decreased viability GR00240-S-1 9.85 COMT
3 Decreased viability GR00249-S 9.85 COMT CRHR1 PSMD9 SLC6A2 SLC6A4 TPH1
4 Decreased viability GR00381-A-1 9.85 CYP2D6 HTR1A HTR3A RGS2 SLC6A4
5 Decreased viability GR00381-A-3 9.85 HTR1A HTR3A SLC6A4
6 Decreased viability GR00386-A-1 9.85 COMT SLC6A2
7 Decreased viability GR00402-S-2 9.85 CYP1A2 CYP2D6 HTR1A HTR3A NPY RGS2

MGI Mouse Phenotypes related to Generalized Anxiety Disorder:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 BDNF COMT CRHR1 CYP1A2 DRD2 HTR1A
2 homeostasis/metabolism MP:0005376 10.27 BDNF COMT CRHR1 CRP CYP1A2 DRD2
3 cardiovascular system MP:0005385 10.21 COMT CRHR1 CRP DRD2 HTR1A MAOA
4 endocrine/exocrine gland MP:0005379 10.18 BDNF COMT CRHR1 CYP1A2 DRD2 HTR2A
5 nervous system MP:0003631 10.07 BDNF COMT CRHR1 DRD2 HTR1A HTR3A
6 muscle MP:0005369 9.92 DRD2 HTR2A HTR3A NR3C1 RGS2 SLC6A3
7 no phenotypic analysis MP:0003012 9.7 BDNF CRHR1 CYP1A2 DRD2 HTR1A NR3C1
8 normal MP:0002873 9.65 BDNF CRHR1 CYP1A2 DRD2 NPY NR3C1
9 respiratory system MP:0005388 9.17 BDNF COMT CRHR1 CYP1A2 DRD2 NR3C1

Drugs & Therapeutics for Generalized Anxiety Disorder

PubMed Health treatment related to Generalized Anxiety Disorder: 62

There are different ways to gradually get a handle on an anxiety disorder . It is unrealistic to expect a quick and simple “cure,” but you can find better ways to deal with stress and anxiety. Medication may also relieve some of the symptoms. There are different kinds of treatment approaches: Psychological treatments : These include approaches like cognitive behavioral therapy . This therapy can help you to learn how to control and then change your thoughts and fears. Relaxation techniques such as autogenic training and progressive muscle relaxation can help you to relax and handle stress better. These techniques are often part of psychological treatment . Medication: The most commonly used medications for anxiety disorders are antidepressants. Some people also use herbal sedatives such as valerian. Self-help: Self-help groups offer you the opportunity to share your thoughts, feelings and experiences with others who have the same condition. Some people also find it helpful to learn more about the disorder – be it from books, information leaflets or on the Internet. It is hard to get a handle on severe anxiety , but many people succeed over time. A therapist can help to reveal the underlying patterns of the worries and anxiety. With their guidance, it is possible to learn how to control harmful thoughts and behavior patterns so that they no longer dominate your life. It can take a lot of patience to find your way back to a life with less anxiety, but a noticeable improvement can often already be achieved after a few weeks.

Drugs for Generalized Anxiety Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 209)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
Norepinephrine Approved Phase 4 51-41-2 439260
Tiagabine Approved, Investigational Phase 4 115103-54-3 60648
Sodium citrate Approved, Investigational Phase 4 68-04-2
Lorazepam Approved Phase 4 846-49-1 3958
Promethazine Approved, Investigational Phase 4 60-87-7 4927
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
Zolpidem Approved Phase 4 82626-48-0 5732
Chamomile Approved, Experimental, Investigational Phase 4
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
Ethanol Approved Phase 4 64-17-5 702
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
Citalopram Approved Phase 4 59729-33-8 2771
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
Ticagrelor Approved Phase 4 274693-27-5 9871419
Atorvastatin Approved Phase 4 134523-00-5 60823
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
Ziprasidone Approved Phase 4 146939-27-7 60854
Methadone Approved Phase 4 76-99-3 4095
Sertraline Approved Phase 4 79617-96-2 68617
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
30 Tandospirone Investigational Phase 4 87760-53-0
Black cohosh Experimental Phase 4
32 Citrate Phase 4
33 Gastrointestinal Agents Phase 4
34 Antiemetics Phase 4
35 GABA Agonists Phase 4
36 Adrenergic alpha-Agonists Phase 4
37 Dopamine agonists Phase 4
38 Vasoconstrictor Agents Phase 4
39 Sympathomimetics Phase 4
40 Excitatory Amino Acid Antagonists Phase 4
41 Antacids Phase 4
42 Anti-Ulcer Agents Phase 4
43 Anesthetics, Dissociative Phase 4
44 Anesthetics, General Phase 4
45 Anesthetics, Intravenous Phase 4
46 Proton Pump Inhibitors Phase 4
47 Parasympatholytics Phase 4
48 Cholinergic Agents Phase 4
49 Muscarinic Antagonists Phase 4
50 Mydriatics Phase 4

Interventional clinical trials:

(show top 50) (show all 461)
# Name Status NCT ID Phase Drugs
1 Escitalopram Treatment of Major Depression in Diabetes Mellitus: An Open Label Unknown status NCT00650897 Phase 4 Escitalopram
2 The Efficacy of Eszopiclone 3 mg as Adjunctive Therapy in Subjects With Insomnia Related to Generalized Anxiety Disorder. Completed NCT00235508 Phase 4 Eszopiclone (Lunesta)
3 Kava for the Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial Completed NCT02219880 Phase 4
4 Duloxetine Versus Placebo in the Treatment of Elderly Patients With Generalized Anxiety Disorder Completed NCT01118780 Phase 4 Duloxetine;Placebo
5 Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder: a Multi-center, Randomized, Usual Dose-controlled Trial Completed NCT01614041 Phase 4 Usual dose treatment of Tandospirone;Comparative high dose of tandospirone treatment
6 Long Term Safety And Efficacy Study Of Pregabalin (Lyrica) In Subjects With Generalized Anxiety Disorder Completed NCT00624780 Phase 4 Pregabalin;Lorazepam;Pregabalin;Placebo
7 Efficacy and Safety of Escitalopram in Patients With Generalized Anxiety Disorder; Open-label, One Arm Postmarketing Study in Russia Completed NCT00902564 Phase 4 Escitalopram
8 Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects Completed NCT01033851 Phase 4
9 A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Current at Least Moderately Severe Anxiety and Lifetime Panic Disorder or Generalized Anxiety Disorder Completed NCT00167479 Phase 4 risperidone (Risperdal)
10 A Randomized, Double-Blind, Placebo-Controlled Study of Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder Completed NCT01172652 Phase 4 Ziprasidone;Placebo
11 Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro) Completed NCT00296790 Phase 4 zolpidem tartrate
12 Chamomile Therapy for Generalized Anxiety Disorder Completed NCT00645983 Phase 4
13 Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder Completed NCT00113295 Phase 4 Continued Paroxetine CR;Quetiapine;Placebo
14 A Multicenter, Randomized, Open-label, Parallel Design Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder Completed NCT00266409 Phase 4 Niravam;SSRI/SNRI
15 Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly Completed NCT00701675 Phase 4 sertraline 50 mg daily;sertraline 100 mg daily;Placebo 50 or 100 mg
16 A Randomized, Double-blind, Placebo-controlled Study of Quetiapine SR and Divalproex Sodium ER on Anxiety in Bipolar Disorder With at Least Moderately Severe Current Anxiety and Lifetime Panic or Generalized Anxiety Disorder. Completed NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
17 Aripiprazole for the Treatment of Refractory Anxiety: Impact on Clinical Outcomes, Resilience and Neuroendocrinologic Parameters Completed NCT00438386 Phase 4 Aripiprazole
18 An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder Completed NCT00961298 Phase 4 Duloxetine
19 Short-term Versus Long-term Treatment in Generalized Anxiety Disorder Completed NCT00183274 Phase 4 Venlafaxine XR;Placebo
20 Enhanced Identification of Very Early Response to Seroquel XR Added to an Antidepressant for the Treatment of Major Depressive Disorder With or Without Generalized Anxiety Disorder Completed NCT00892463 Phase 4 Quetiapine (Seroquel) XR
21 Coordinated Anxiety Learning and Management (CALM): Improving Primary Care Anxiety Outcomes Completed NCT00347269 Phase 4 Psychotropic medication optimization
22 A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients (MOSAIC) Completed NCT01201967 Phase 4
23 Cognitive-Behavioral Therapy and Pharmacotherapy Augmentation for Generalized Anxiety Disorder: A Pilot Investigation Completed NCT00219349 Phase 4 escitalopram
24 Pharmacotherapy of Late-Life Generalized Anxiety Disorder Completed NCT00105586 Phase 4 Escitalopram
25 Randomized, Double-blind, Placebo-controlled Study of a Benzodiazepine vs Placebo on Functional Magnetic Resonance Imaging (fMRI) of the Brain, and on Behavioral/Clinical Measures in Patients With Generalized Anxiety Disorder Completed NCT00662259 Phase 4 Alprazolam (Xanax);Placebo
26 Black Cohosh Therapy for Menopause-Related Anxiety Completed NCT00120458 Phase 4
27 Long-Term Lorazepam Use and Acute Toxicity in the Aged Completed NCT00044642 Phase 4 Lorazepam
28 Efficacy of Rapid-Acting NMDA Antagonist for Treatment of Adolescent Depression and Anxiety Disorders Completed NCT02579928 Phase 4 Ketamine;Midazolam
29 A Double-Blind, Placebo-Controlled, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults Completed NCT01224067 Phase 4 Quetiapine
30 A Pilot Study of Cranial Electrotherapy Stimulation[CES] for Generalized Anxiety Disorder Completed NCT00539357 Phase 4
31 The Use of Acamprosate in Individuals With Alcohol Dependence and Comorbid Anxiety or Depression Completed NCT00330174 Phase 4 Acamprosate
32 Aripiprazole (Abilify) Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4 Aripiprazole
33 A Double-blind, Controlled, Randomized Study Comparing Escitalopram Combined With Scopolamine or Escitalopram in Patients With Major Depressive Disorder Completed NCT03131050 Phase 4 Scopolamine;Escitalopram;Saline
34 Microtuning a Bonafide Treatment for GAD Patients - A Randomized Controlled Trial. Completed NCT02039193 Phase 4
35 A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and Tolerability of Immediate-Release Formulation of Quetiapine Fumarate as Potentiation of Selective Serotonin Reuptake Inhibitors, and Serotonin Norepinephrine Reuptake Inhibitors Treatment in Major Depression With Comorbid Anxiety Symptoms Completed NCT00229645 Phase 4 Quetiapine Fumarate (Seroquel®)
36 Role of Gastroesophageal Acid Reflux at Squamo-columnar Junction in Functional Dyspepsia Completed NCT01349413 Phase 4 Esomeprazole 20mg
37 A 14 Week Open-Label Study to Evaluate the Tolerability of Switching From an SSRI to Tiagabine(GABITRIL) in Order to Alleviate SSRI Induced Sexual Dysfunction in Generalized Anxiety Disorder Patients Completed NCT00174850 Phase 4 Gaitril
38 A Pilot Study to Treat Emotional Disorders in Primary Care With Evidence-based Psychological Techniques: A Randomized Controlled Trial Completed NCT01903096 Phase 4 Primary Care Treatment As Usual
39 Efficacy of Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) Treatment on Prefrontality in Patients With Generalized Anxiety Disorder (GAD) and Other Comorbidities Recruiting NCT01975480 Phase 4 Desvenlafaxine
40 Interventional, Open-label Effectiveness Study of Flexible Doses of Vortioxetine on Depressive Symptoms in Patients With Major Depressive Disorder Comorbid With Generalized Anxiety Disorder Recruiting NCT04220996 Phase 4 Vortioxetine
41 Comparative Effectiveness of Mindfulness-Based Stress Reduction and Pharmacotherapy for Anxiety Recruiting NCT03522844 Phase 4 Escitalopram
42 Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty: A Double-blinded Randomized Control Trial Enrolling by invitation NCT03271151 Phase 4 Cymbalta
43 The Success of Opening Concurrent Chronic Total Occlusion leSion to Improve Cardiac Function Trial in Patients With Multi-vessel Disease (SOS-moral): Study Protocol of a Prospective Multicenter Study Enrolling by invitation NCT03372785 Phase 4 aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor
44 Ziprasidone for the Treatment of Generalized Anxiety Comorbidity in Patients With Bipolar Disorder Terminated NCT00374543 Phase 4 Ziprasidone;Placebo
45 A Prospective, Sixteen-Week, Double-Blind, Placebo-Controlled, Trial of Seroquel in Combination With Treatment as Usual in Patients With GAD and Remitted Comorbid Opiate Dependence Terminated NCT00668265 Phase 4 Quetiapine
46 Sertraline in the Treatment of Generalized Social Phobia With Comorbidity Terminated NCT00182533 Phase 4 Sertraline;Placebo
47 An Open Label, Randomized Study Prospectively Examining the Effect on Anxiety in Partial Epilepsy Patients Treated With Pregabalin Terminated NCT01128712 Phase 4 Pregabalin;Pregabalin
48 An Open-label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines in Treatment-refractory Patients With Unipolar Depression or Generalized Anxiety Disorder and Chronic Benzodiazepine Use Terminated NCT01244711 Phase 4 quetiapine
49 Effects of Buspar on Depressive Symptom Improvement and Neuroprotection in Patients With Anxiety Disorder Withdrawn NCT01546896 Phase 4 buspirone+alprazolam;alprazolam
50 The Effect of Saffron (Crocus Satious L.) in the Treatment of Mild to Moderate Generalized Anxiety Disorder: a Double Blind Randomized Controlled Trial Unknown status NCT02800733 Phase 2, Phase 3

Search NIH Clinical Center for Generalized Anxiety Disorder

Genetic Tests for Generalized Anxiety Disorder

Anatomical Context for Generalized Anxiety Disorder

MalaCards organs/tissues related to Generalized Anxiety Disorder:

Brain, Heart, Testes, Breast, Amygdala, Cortex, Eye

Publications for Generalized Anxiety Disorder

Articles related to Generalized Anxiety Disorder:

(show top 50) (show all 6100)
# Title Authors PMID Year
Duloxetine in the treatment of generalized anxiety disorder. 54 61
19337457 2008
Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study. 61 54
18840371 2008
Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. 54 61
18344738 2008
Azapirones for generalized anxiety disorder. 54 61
16856115 2006
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. 61 54
16722631 2006
Early response and 8-week treatment outcome in GAD. 61 54
16845651 2006
Serotonin transporter and tryptophan hydroxylase gene polymorphisms in Chinese patients with generalized anxiety disorder. 54 61
15722951 2005
SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder. 54 61
15538601 2004
Association studies of MAO-A, COMT, and 5-HTT genes polymorphisms in patients with anxiety disorders of the phobic spectrum. 61 54
15450911 2004
Occupancy of agonist drugs at the 5-HT1A receptor. 54 61
14985704 2004
Association of a MAOA gene variant with generalized anxiety disorder, but not with panic disorder or major depression. 54 61
12555227 2003
Serotonin, 5-hydroxyindoleacetic acid and serotonin transporter in blood peripheral lymphocytes of patients with generalized anxiety disorder. 61 54
12188031 2002
Serotonergic polymorphisms in patients suffering from alcoholism, anxiety disorders and narcolepsy. 54 61
11444684 2001
Inverse agonist binding of peripheral benzodiazepine receptors in anxiety disorder. 61 54
11697575 2001
Decreased platelet peripheral-type benzodiazepine receptors in adolescent inpatients with repeated suicide attempts. 54 61
10459397 1999
Benzodiazepine-induced chemotaxis is impaired in monocytes from patients with generalized anxiety disorder. 61 54
10101731 1999
Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety. 54 61
10356651 1999
Peripheral benzodiazepine receptor messenger RNA is decreased in lymphocytes of generalized anxiety disorder patients. 61 54
9606532 1998
Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis. 61 54
9399689 1997
[The 5-HT1A receptor: a new effective principle in psychopharmacologic therapy?]. 54 61
9064274 1996
Altered platelet peripheral-type benzodiazepine receptor in posttraumatic stress disorder. 54 61
8866701 1996
A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. 61 54
8748432 1995
Efficacy trial of the 5-HT2 antagonist MDL 11,939 in patients with generalized anxiety disorder. 61 54
7714223 1995
The role of serotonin in depression and anxiety. 61 54
7622823 1995
Single-site findings in a study of the safety and efficacy of a CCKB receptor antagonist, CI-988, in the treatment of generalized anxiety disorder. 54 61
9160582 1994
Peripheral-type benzodiazepine receptors in anxiety disorders. 54 61
1686517 1991
Risk perception in paranoia and anxiety: Two investigations across clinical and non-clinical populations. 61
32547929 2020
Affect variability and emotional reactivity in generalized anxiety disorder. 61
31896042 2020
Difference in binocular rivalry rate between major depressive disorder and generalized anxiety disorder. 61
32461128 2020
Women with Major Depressive Disorder, Irrespective of Comorbid Anxiety Disorders, Show Blunted Bilateral Frontal Responses during Win and Loss Anticipation. 61
32421596 2020
Depression with and without a history of psychotic symptoms in the general population: sociodemographic and clinical characteristics. 61
32423890 2020
Mental disorders in Spanish university students: Prevalence, age-of-onset, severe role impairment and mental health treatment. 61
32560960 2020
Associations of Caregiver-Oncologist Discordance in Prognostic Understanding With Caregiver-Reported Therapeutic Alliance and Anxiety. 61
32061833 2020
Association of exposure to Toxoplasma gondii, Epstein-Barr Virus, Herpes Simplex virus Type 1 and Cytomegalovirus with new-onset depressive and anxiety disorders: An 11-year follow-up study. 61
31809804 2020
Goal-focused positive psychotherapy in action: A case study. 61
31926022 2020
Is scan-negative cauda equina syndrome a functional neurological disorder? A pilot study. 61
32073712 2020
Accuracy of the Diagnostic Infant and Preschool Assessment (DIPA) in a Dutch sample. 61
32360141 2020
Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptoms. 61
31806360 2020
Association of stress-related sleep disturbance with psychiatric symptoms among pregnant women. 61
32193051 2020
Abnormal night sleep duration and inappropriate sleep initiation time are associated with elevated anxiety symptoms in Chinese rural adults: the Henan Rural Cohort. 61
32574900 2020
The Relationship between Physical Activity Levels and Mental Health in Individuals with Spinal Cord Injury in South Korea. 61
32575553 2020
Cross-cultural adaptation and validation of the Turkish version of Centrality of Pain Scale in patients with fibromyalgia syndrome. 61
32207222 2020
Prevalence and Factors Associated with Insomnia Among a Representative Sample of the Lebanese Population: Results of a Cross-Sectional Study. 61
32538027 2020
Effects of a forehead cooling device in veterans with chronic insomnia disorder and co-morbid medical and psychiatric conditions: a pilot study. 61
32572683 2020
Noise annoyance predicts symptoms of depression, anxiety and sleep disturbance 5 years later. Findings from the Gutenberg Health Study. 61
32034913 2020
The Effects of Apnea Training, Using Voluntary Breath Holds, on High Altitude Acclimation: Breathe-High Altitude Study. 61
32267783 2020
Bodily changes and sensory sensitivity in complex regional pain syndrome and fibromyalgia. 61
32049896 2020
Prevalence of Positive Mental Health and Associated Factors Among Postpartum Women in Canada: Findings from a National Cross-Sectional Survey. 61
32323116 2020
Thoughts of self-harm and associated risk factors among postpartum women in Canada. 61
32292178 2020
Assessment of anxiety and depression in patients with incidental pulmonary nodules and analysis of its related impact factors. 61
32212379 2020

Variations for Generalized Anxiety Disorder

Expression for Generalized Anxiety Disorder

Search GEO for disease gene expression data for Generalized Anxiety Disorder.

Pathways for Generalized Anxiety Disorder

Pathways related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
11.65 TPH1 MAOA CYP1A2
Show member pathways
11.51 CYP2D6 CYP1A2 COMT
Show member pathways
11 11.25 MAOA CYP2D6 CYP1A2
Show member pathways
Show member pathways
Show member pathways
10.84 HTR3A CYP2D6 CYP1A2
Show member pathways
17 10.71 MAOA COMT
18 10.56 MAOA CYP2D6 CYP1A2
Show member pathways

GO Terms for Generalized Anxiety Disorder

Cellular components related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.92 SLC6A4 SLC6A3 SLC6A2 HTR3A HTR2A HTR1A
2 synapse GO:0045202 9.85 SLC6A4 NPY HTR3A HTR2A HTR1A DRD2
3 dendrite GO:0030425 9.8 HTR2A HTR1A DRD2 COMT BDNF
4 axon GO:0030424 9.73 SLC6A3 HTR3A HTR2A DRD2 COMT BDNF
5 neuron projection GO:0043005 9.7 TPH1 SLC6A4 SLC6A3 SLC6A2 RGS2 HTR3A
6 dopaminergic synapse GO:0098691 9.43 SLC6A3 DRD2
7 integral component of presynaptic membrane GO:0099056 9.35 SLC6A4 SLC6A3 HTR3A HTR2A DRD2
8 integral component of postsynaptic membrane GO:0099055 9.02 SLC6A4 SLC6A3 HTR3A HTR2A DRD2

Biological processes related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.83 SLC6A2 NPY HTR3A HTR2A HTR1A
2 circadian rhythm GO:0007623 9.81 TPH1 SLC6A4 BDNF
3 memory GO:0007613 9.81 SLC6A4 HTR2A BDNF
4 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.77 NPY HTR2A HTR1A
5 response to ethanol GO:0045471 9.76 SLC6A3 RGS2 HTR3A DRD2
6 neurotransmitter transport GO:0006836 9.72 SLC6A4 SLC6A3 SLC6A2
7 response to cocaine GO:0042220 9.71 SLC6A3 HTR3A DRD2
8 feeding behavior GO:0007631 9.7 NPY DRD2 BDNF
9 transport GO:0006810 9.69 SLC6A4 SLC6A3 SLC6A2
10 vasoconstriction GO:0042310 9.67 SLC6A4 HTR1A
11 negative regulation of voltage-gated calcium channel activity GO:1901386 9.67 DRD2 CRHR1
12 oxidative demethylation GO:0070989 9.66 CYP2D6 CYP1A2
13 prepulse inhibition GO:0060134 9.66 SLC6A3 DRD2
14 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.65 HTR2A DRD2
15 dopamine metabolic process GO:0042417 9.65 DRD2 COMT
16 behavior GO:0007610 9.65 HTR2A HTR1A
17 neurotransmitter biosynthetic process GO:0042136 9.64 SLC6A4 SLC6A3
18 catecholamine metabolic process GO:0006584 9.63 MAOA COMT
19 neurotransmitter catabolic process GO:0042135 9.62 MAOA COMT
20 regulation of dopamine metabolic process GO:0042053 9.62 SLC6A3 HTR1A
21 adenohypophysis development GO:0021984 9.61 SLC6A3 DRD2
22 hyaloid vascular plexus regression GO:1990384 9.61 SLC6A3 DRD2
23 neurotransmitter reuptake GO:0098810 9.6 SLC6A4 SLC6A2
24 heterocycle metabolic process GO:0046483 9.58 CYP2D6 CYP1A2
25 drug catabolic process GO:0042737 9.58 CYP2D6 CYP1A2
26 monoterpenoid metabolic process GO:0016098 9.57 CYP2D6 CYP1A2
27 dopamine uptake involved in synaptic transmission GO:0051583 9.56 SLC6A3 SLC6A2
28 estrogen metabolic process GO:0008210 9.54 CYP2D6 CYP1A2 COMT
29 response to pain GO:0048265 9.5 TSPO SLC6A2 COMT
30 norepinephrine uptake GO:0051620 9.49 SLC6A3 SLC6A2
31 norepinephrine transport GO:0015874 9.48 SLC6A3 SLC6A2
32 dopamine catabolic process GO:0042420 9.43 SLC6A3 MAOA COMT
33 alkaloid metabolic process GO:0009820 9.4 CYP2D6 CYP1A2
34 monoamine transport GO:0015844 9.33 SLC6A4 SLC6A3 SLC6A2
35 response to drug GO:0042493 9.28 TSPO SLC6A4 SLC6A3 SLC6A2 HTR2A DRD2
36 serotonin receptor signaling pathway GO:0007210 9.13 HTR3A HTR2A HTR1A

Molecular functions related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 monooxygenase activity GO:0004497 9.61 TPH1 CYP2D6 CYP1A2
2 neurotransmitter receptor activity GO:0030594 9.58 HTR3A HTR2A HTR1A
3 dopamine binding GO:0035240 9.46 SLC6A3 DRD2
4 drug binding GO:0008144 9.46 SLC6A3 HTR2A DRD2 CYP2D6
5 neurotransmitter:sodium symporter activity GO:0005328 9.43 SLC6A4 SLC6A3 SLC6A2
6 dopamine:sodium symporter activity GO:0005330 9.37 SLC6A3 SLC6A2
7 norepinephrine:sodium symporter activity GO:0005334 9.32 SLC6A3 SLC6A2
8 monoamine transmembrane transporter activity GO:0008504 9.13 SLC6A4 SLC6A3 SLC6A2
9 serotonin binding GO:0051378 8.92 SLC6A4 HTR3A HTR2A HTR1A

Sources for Generalized Anxiety Disorder

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....